Shire’s Vyvanse Getting Increased Attention From ADHD Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Attention deficit/hyperactivity disorder drug gained a 2.8 percent share of the market two months after its launch, Shire reports.